162 related articles for article (PubMed ID: 6818040)
1. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Sakoda S; Ueji M; Hayashi A; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1982; 23(5):463-8. PubMed ID: 6818040
[TBL] [Abstract][Full Text] [Related]
2. Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Tsuge I; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1980 Jun; 17(6):429-35. PubMed ID: 6772451
[TBL] [Abstract][Full Text] [Related]
3. Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.
Azuma T; Suzuki T; Mizuno R; Tsujino S; Kishimoto S; Mizuta E; Ichikawa K
Acta Neurol Scand; 1988 May; 77(5):409-13. PubMed ID: 3137768
[TBL] [Abstract][Full Text] [Related]
4. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
5. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
Suzuki T; Sakoda S; Ueji M; Kishimoto S
Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
[TBL] [Abstract][Full Text] [Related]
7. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.
Suzuki T; Higa S; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
Neurology; 1981 Oct; 31(10):1323-6. PubMed ID: 6287350
[TBL] [Abstract][Full Text] [Related]
8. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
[TBL] [Abstract][Full Text] [Related]
9. Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.
Morimoto S; Matsumura Y; Ohyama T; Shinyama H; Ichihara T; Takahashi Y; Hisaki K
Jpn J Pharmacol; 1990 Mar; 52(3):431-9. PubMed ID: 2110272
[TBL] [Abstract][Full Text] [Related]
10. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.
Araki H; Tanaka C; Fujiwara H; Nakamura M; Ohmura I
J Pharm Pharmacol; 1981 Dec; 33(12):772-7. PubMed ID: 6121848
[TBL] [Abstract][Full Text] [Related]
11. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
12. Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy.
Ando Y; Gotoh T; Kawaguchi Y; Tanaka Y; Sakashita N; Ando M
Pharmacotherapy; 1995; 15(3):345-9. PubMed ID: 7667168
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Azuma T; Suzuki T; Sakoda S; Mizuno R; Tsujino S; Kobayashi T; Kishimoto S; Hiraga T; Matsubara T; Yoshida S
Acta Neurol Scand; 1991 Jul; 84(1):46-50. PubMed ID: 1656690
[TBL] [Abstract][Full Text] [Related]
14. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
15. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart.
Ohmura I; Inagaki C; Araki H; Tanaka C
Jpn J Pharmacol; 1978 Oct; 28(5):747-53. PubMed ID: 31501
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
Yamamoto M; Ujike H; Ogawa N
Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
[TBL] [Abstract][Full Text] [Related]
18. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Yamamoto M; Ogawa N; Ujike H
J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.
Goldstein DS; Holmes C; Kaufmann H; Freeman R
Clin Auton Res; 2004 Dec; 14(6):363-8. PubMed ID: 15666063
[TBL] [Abstract][Full Text] [Related]
20. A new metabolic pathway of L-threo-3,4-dihydroxyphenylserine, a precursor amino acid of norepinephrine, in the brain. Studies by in vivo microdialysis.
Maruyama W; Nakahara D; Naoi M
J Neural Transm Park Dis Dement Sect; 1994; 7(1):21-33. PubMed ID: 8579767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
